DOCSLIB.ORG

Other As Well (Not Just with Teva)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Other As Well (Not Just with Teva) No. 19-1010 ================================================================================================================ In The Supreme Court of the United States --------------------------------- ♦ --------------------------------- ACTAVIS HOLDCO US, INC., et al., Petitioners, v. STATE OF CONNECTICUT, et al., Respondents. --------------------------------- ♦ --------------------------------- On Petition For Writ Of Certiorari To The United States Court Of Appeals For The Third Circuit --------------------------------- ♦ --------------------------------- RESPONDENTS’ APPENDIX TO BRIEF IN OPPOSITION TO PETITION FOR WRIT OF CERTIORARI --------------------------------- ♦ --------------------------------- WILLIAM TONG Attorney General of Connecticut *CLARE KINDALL Solicitor General W. J OSEPH NIELSEN ROBERT J. DEICHERT Assistant Attorneys General OFFICE OF THE ATTORNEY GENERAL 165 Capitol Avenue Hartford, CT 06106 (860) 808-5261 [email protected] Counsel for State of Connecticut and Liaison Counsel for Respondent States *Counsel of Record (Additional Counsel On Inside Cover And On Signature Pages) ================================================================================================================ ROBERTA D. LIEBENBERG JEFFREY S. ISTVAN FINE, KAPLAN AND BLACK, R.P.C. One South Broad Street, 23rd Floor Philadelphia, PA 19107 (215) 567-6565 rliebenberg@finekaplan.com Lead Counsel for the End-Payer Plaintiffs DIANNE M. NAST NASTLAW LLC 1101 Market Street, Suite 2801 Philadelphia, PA 19107 (215) 923-9300 [email protected] Lead Counsel for the Direct Purchaser Plaintiffs JONATHAN W. C UNEO CUNEO, GILBERT & LADUCA LLP 4725 Wisconsin Avenue, NW, Suite 200 Washington D.C. 20016 (202) 789-3960 [email protected] Lead Counsel for Indirect Reseller Plaintiffs WILLIAM J. BLECHMAN KENNY NACHWALTER P.A. 1441 Brickell Avenue, Suite 1100 Miami, FL 33131 (305) 373-1000 [email protected] Counsel for the Kroger Direct Action Plaintiffs and Liaison Counsel for Direct Action Plaintiffs Ai APPENDIX TABLE OF CONTENTS (1) List of Plaintiffs-Respondents .......................... A1 (2) In re: Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724, Docket no. 16-MD-2724, List of Drugs at Issue .................................................... A5 (3) In re: Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724, Docket no. 16-MD-2724, Excerpts from States' Amended Complaint (E.D. PA, doc. no. 106, October 31, 2019) ..................... A10 (4) In re: Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724, Docket no. 16-MD-2724 Excerpts from Plaintiff States' Consolidated Amended Complaint (E.D. PA, doc. no. 15, June 15, 2018) (unsealed version--previously sealed portions reproduced in grayscale pursuant to district court's order) .................................................................... A71 (5) In re: Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724, Docket no. 16-MD-2724, Pretrial Order No. 70 (E.D. PA, doc. no. 841, January 31, 2019) ............................................... A92 (6) In re: Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724, Docket no. 16-MD-2724, Plaintiff States' Response & Objections to Special Master David H. Marion's August 16, 2019 Report and Recommended Order Setting Forth a Case Management Order and Discovery Schedule (E.D. PA, doc. no. 1086, September 13, 2019) ........... A103 Aii (7) In re: Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724, Docket no. 16-MD-2724, Plaintiffs' Response to August 16, 2019 Report and Recommended Order From Special Master David H. Marion Setting Forth a Recommended Case Management Order and Discovery Schedule (E.D. PA, doc. no. 1092, September 13, 2019) .. A126 (8) In re: Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724, Docket no. 16-MD-2724, Excerpts from Transcript of Proceedings (E.D. PA, doc. no. 1128, September 24, 2019) ................... A166 (9) In re: Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724, Docket no. 16-MD-2724, Memorandum Opinion (E.D. PA, doc. no. 1191, January 9, 2020) ................................................ A197 A1 LIST OF PLAINTIFFS-RESPONDENTS State Respondents State of Connecticut State of Alabama State of Alaska Territory of American Samoa State of Arizona State of Arkansas State of California State of Colorado State of Delaware District of Columbia State of Florida State of Georgia Territory of Guam State of Hawaii State of Idaho State of Illinois State of Indiana State of Iowa State of Kansas Commonwealth of Kentucky State of Louisiana State of Maine State of Maryland Commonwealth of Massachusetts State of Michigan State of Minnesota State of Mississippi State of Missouri State of Montana State of Nebraska State of Nevada State of New Hampshire A2 State of New Jersey State of New Mexico State of New York State of North Carolina State of North Dakota Commonwealth of the Northern Mariana Islands State of Ohio State of Oklahoma State of Oregon Commonwealth of Pennsylvania Commonwealth of Puerto Rico State of Rhode Island State of South Carolina State of South Dakota State of Tennessee State of Utah State of Vermont Commonwealth of Virginia State of Washington State of West Virginia State of Wisconsin State of Wyoming Direct Purchaser Respondents (Named Plaintiffs) KPH Healthcare Services, Inc., a/k/a Kinney Drugs, Inc. FWK Holdings, LLC Rochester Drug Co‐Operative, Inc. César Castillo, Inc. Ahold USA, Inc. End-Payor Respondents (Named Plaintiffs): 1199SEIU Greater New York Benefit Fund A3 1199SEIU Licensed Practical Nurses Welfare Fund 1199SEIU National Benefit Fund 1199SEIU National Benefit Fund for Home Care Workers American Federation of State, County and Municipal Employees District Council 37 Health & Security Plan American Federation of State, County and Municipal Employees District Council 47 Health & Welfare Fund City of Providence, Rhode Island Detectives Endowment Association of the City of New York Nina Diamond Hennepin County International Union of Operating Engineers Local 30 Benefits Fund Robby Johnson Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana Ottis McCrary Philadelphia Federation of Teachers Health and Welfare Fund Self-Insured Schools of California Sergeants Benevolent Association of the Police Department of the City of New York Health and Welfare Fund David Sherman UFCW Local 1500 Welfare Fund Uniformed Fire Officers Association Family Production Plan Local 854 Unite Here Health United Food & Commercial Workers and Employers Arizona Health & Welfare Trust Valerie Velardi A4 Indirect-Reseller Respondents (Named Plaintiffs): Mr. Russell’s Discount Drugs, Inc. Falconer Pharmacy, Inc. Reliable Pharmacy, Inc. Chet Johnson Drug, Inc. Halliday’s and Koivisto’s Pharmacy Direct Action Respondents: The Kroger Co. Albertsons Companies, LLC H.E. Butt Grocery Company L.P. Humana, Inc. United Healthcare Services, Inc. A5 In re Generic Pharmaceuticals Pricing Antitrust Litigation 2:16-md-2724-CMR (MDL 2724) List of Drugs at Issue 1. Acetazolamide 2. Acyclovir 3. Adapalene 4. Albuterol 5. Alclometasone Dipropionate 6. Allopurinol 7. Amantadine HCL 8. Amiloride HCL/HCTZ 9. Amitriptyline 10 Amoxicillin/Clavulanate 11. Amphetamine/Dextroamphetamine 12. Atenolol Chlorthalidone 13. Atropine Sulfate 14. Azithromycin 15. Baclofen 16. Balsalazide Disodium 17. Benazepril HCTZ 18. Betamethasone Dipropionate 19. Betamethasone Dipropionate Augmented 20. Betamethasone Dipropionate Clotrimazole 21. Betamethasone Valerate 22. Bethanechol Chloride 23. Bromocriptine Mesylate 24. Budesonide 25. Bumetanide 26. Buprenorphine 27. Buprenorphine Naloxone 28. Buspirone Hydrochloride 29. Butorphanol Tartrate 30. Cabergoline 31. Capecitabine 32. Captopril 33. Carbamazepine 34. Carisoprodol 35. Cefdinir 36. Cefprozil 37. Cefuroxime Axetil 38. Celecoxib 39. Cephalexin (Cefalexin) A6 40. Chlorpromazine HCL 41. Cholestyramine 42. Ciclopirox 43. Cimetidine 44. Ciprofloxacin HCL Tablet 45. Clarithromycin 46. Clemastine Fumarate 47. Clindamycin Phosphate 48. Clobetasol 49. Clomipramine HCL 50. Clonidine TTS 51. Clotrimazole 52. Cyproheptadine HCL 53. Desmopressin Acetate 54. Desonide 55. Desogestrel and Ethinyl Estradiol [Kariva] 56. Dexmethylphenidate HCL [Focalin] 57. Dextroamphetamine Sulfate (“Dex Sulfate”) 58. Diclofenac Potassium 59. Dicloxacillin Sodium 60. Diflunisal 61. Digoxin 62. Diltiazem HCL 63. Diphenoxylate Atropine HCL 64. Disopyramide Phosphate 65. Disulfiram 66. Divalproex 67. Doxazosin Mesylate 68. Doxycycline 69. Doxycycline Hyclate 70. Doxycycline Monohydrate 71. Drospirenone and Ethinyl Estradiol 72. Econazole 73. Enalapril Maleate 74. Entecavir 75. Eplerenone 76. Epitol 77. Estazolam 78. Estradiol 79. Estradiol and Norethindrone Acetate [Mimvey] 80. Ethinyl Estradiol and Levonorgestrel [Portia and Jolessa] 81. Ethosuximide 82. Etodolac 83. Exemestane A7 84. Fenofibrate 85. Fluconazole 86. Fluocinonide 87. Fluocinolone Acetonide 88. Fluoxetine HCL 89. Flurbiprofen 90. Flutamide 91. Fluticasone Propionate 92. Fluvastatin Sodium 93. Fosinopril HCTZ 94. Gabapentin 95. Glimepiride 96. Glipizide-Metformin 97. Glyburide 98. Glyburide-Metformin 99. Griseofulvin 100. Halobetasol Propionate 101. Haloperidol 102. Hydralazine 103. Hydrocodone Acetaminophen 104. Hydrocortisone Valerate 105. Hydroxyurea 106. Hydroxyzine Pamoate 107. Imiquimod 108. Irbesartan 109. Isoniazid 110. Isosorbide Dinitrate 111. Isotretinoin 112. Ketoconazole 113. Ketoprofen 114. Ketorolac Tromethamine 115. Labetalol HCL 116.
Load more

Recommended publications
  • 1 | Page Danae Christodoulou, US Food and Drug Administration
    Bios Danae Christodoulou, US Food and Drug Administration [email protected] Danae Christodoulou is an Acting Branch Chief in the Office of New Drug Products/OPQ/CDER. Danae joined FDA in 1998 and served as primary reviewer in the Office of New Drugs, as a Chemistry, Manufacturing and Controls Lead and Acting Branch Chief since 2013. Danae has a background in Inorganic Chemistry and received her Ph.D. from the University of Michigan, Ann Arbor, MI. Prior to FDA, Danae worked at Johnson Matthey Inc. R&D Drug Discovery as a Senior Research Chemist and at the National Cancer Institute, in Frederick, MD. Danae served as the Chair for the EI Implementation Working Group at FDA. Marjorie Coppinger, Teva [email protected] Marjorie Coppinger is Head of Global Generic Research Quality (SOD/SSL) for Teva Pharmaceuticals. She received B.A in Chemistry from the University of Notre Dame, Maryland and has over 21 years of experience at Teva Pharmaceuticals in analytical research and development, technical services, manufacturing, quality control, compendial compliance and quality assurance. Currently Ms. Coppinger is Co- Chair of the NJPQCA Compendial Discussion Group and has represented both NJPQCA and GPhA on various USP planning meetings, stakeholder initiatives and project groups for the USP. Elisabeth Corbett, Bristol-Myers Squibb. [email protected] Elisabeth Corbett is an Associate Director, CMC, in Global Regulatory Sciences at Bristol-Myers Squib in Pennington, NJ. She joined Bristol-Myers Squibb as a process engineer in Process Chemistry R&D in 2001. In 2008, she relocated to San Antonio, Texas and served in Quality roles before returning to CMC Regulatory at BMS in 2012.
    [Show full text]
  • Teva to Acquire Cogenesys
    TEVA PHARMACEUTICALS AND PERRIGO COMPANY ANNOUNCE THE U.S. LAUNCH OF GENERIC TEMOZOLOMIDE Jerusalem and Allegan, Mich. – August 12, 2013 – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Perrigo Company (NYSE: PRGO;TASE) today announced the launch of the generic equivalent to Temodar® (temozolomide). Teva will manufacture, market and distribute the product in the U.S. and both companies will equally share in the cost and profitability of the product in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. This product is the generic equivalent to Temodar® (temozolomide), indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. Temodar® had annual sales of approximately $423 million in the United States, according to IMS data as of December 31, 2012. The launch of this product provides a quality alternative, making cancer therapy more cost effective for patients who suffer from this devastating cancer. Perrigo’s Chairman, President and CEO Joseph C. Papa stated, “This first-to-file launch with our partner Teva is another example of our focus to manufacture complex API’s. We are pleased to offer this important product to patients in the United States.” “We are pleased to partner with Perrigo to offer patients a high-quality, less expensive alternative of this important medicine. This launch demonstrates Teva’s commitment to continue to pursue first-to-market opportunities and enhance the value of our portfolio by concentrating on high-margin, low competition markets,” stated Allan Oberman, President and CEO of Teva Americas Generics.
    [Show full text]
  • Teva Respiratory LLC V. Perrigo Pharmaceuticals
    Case 1:20-cv-00207 ECF No. 1 filed 03/09/20 PageID.1 Page 1 of 21 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF MICHIGAN ) ) TEVA RESPIRATORY, LLC, and TEVA ) PHARMACEUTICALS USA, INC., ) ) Civil Action No. 20-00207 ) Plaintiffs, ) ) v. ) ) PERRIGO PHARMACEUTICALS CO., and ) PERRIGO COMPANY PLC, ) ) Defendants. ) ) ) COMPLAINT Plaintiffs Teva Respiratory, LLC (“Teva Respiratory”) and Teva Pharmaceuticals USA, Inc. (“Teva USA”) (collectively, “Plaintiffs” or “Teva”), allege against defendants Perrigo Pharmaceuticals Co., and Perrigo Company plc (collectively, “Defendants” or “Perrigo”) as follows: INTRODUCTION 1. This case arises from Perrigo’s deliberate and unlawful attempt to misappropriate Teva’s federally registered trade dress for Teva’s revolutionary ProAir RespiClick® rescue respiratory inhaler and usurp and tarnish Teva’s goodwill. 2. Teva’s ProAir RespiClick® is the only albuterol rescue inhaler on the market that is “breath-activated”; it does not require any hand-breath coordination during inhalation. In other words, Teva’s ProAir RespiClick® enables users to get a rescue dose of albuterol during an asthma or COPD attack simply by breathing in. ProAir RespiClick® is a leading drug for the treatment of bronchospasm. -1- ACTIVE/102581507.4 Case 1:20-cv-00207 ECF No. 1 filed 03/09/20 PageID.2 Page 2 of 21 3. Teva’s ProAir RespiClick® design includes a white body and a distinctive red cap. Teva has a federally registered trademark on the ProAir RespiClick® design. 4. Teva also sells an earlier-generation albuterol rescue inhaler named ProAir® HFA, both as a branded product and as an authorized generic product.
    [Show full text]
  • Wellbutrin Xl : Civil Action Antitrust Litigation : : : No
    Case 2:08-cv-02433-GAM Document 419 Filed 05/11/12 Page 1 of 95 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: WELLBUTRIN XL : CIVIL ACTION ANTITRUST LITIGATION : : : NO. 08-2431 (direct) : NO. 08-2433 (indirect) MEMORANDUM McLaughlin, J. May 11, 2012 TABLE OF CONTENTS Page I. Legal and Factual Background.. 2 A. The Drug Approval Process and Regulatory Framework. 2 B. The Citizen Petition Process. 4 C. Wellbutrin IR, Wellbutrin SR, and Wellbutrin XL.. 5 D. Noerr-Pennington Immunity and the Sham Exception. 7 E. Standard of Proof as to Objective Baselessness. 11 II. Overview.. 13 III. Biovail’s Conduct. 15 A. The Anchen Lawsuit. 15 B. The Watson Lawsuit. 26 C. The Abrika Lawsuit. 28 D. The Impax Lawsuit.. 43 E. The Citizen Petition. 50 IV. GSK’s Conduct. 82 A. The Impax and Watson Lawsuits.. 84 B. Biovail’s Citizen Petition. 86 Case 2:08-cv-02433-GAM Document 419 Filed 05/11/12 Page 2 of 95 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: WELLBUTRIN XL : CIVIL ACTION ANTITRUST LITIGATION : : : NO. 08-2431 (direct) : NO. 08-2433 (indirect) MEMORANDUM McLaughlin, J. May 11, 2012 Wellbutrin XL is a once-a-day antidepressant containing the active pharmaceutical ingredient bupropion hydrochloride. It is produced by Biovail Corporation, Biovail Laboratories, Inc., and Biovail Laboratories International SRL1 (together, “Biovail”), and distributed by SmithKline Beecham Corporation and GlaxoSmithKline, PLC (together, “GSK”). The plaintiffs, direct and indirect purchasers of Wellbutrin XL, have sued Biovail and GSK for illegally conspiring to prevent generic versions of Wellbutrin XL from entering the American market by filing sham patent infringement lawsuits and a citizen petition with the Food and Drug Administration (“FDA”), and entering into agreements with generic companies to settle the lawsuits.
    [Show full text]
  • Organization Exempt from Rnr Ome T^"
    XTENDEDG^TO NOVEMBER 15,1-201 Return'o4- Organization Exempt From rnr ome T^". OMB No 1545-0047 Form 990 Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundat Do not enter social security numbers on this form as it may be made public. Department of the Treasury ► Internal Revenue Service Pop, Information about Form 990 and its instructions is at www.1rs. gov/form990. A For the 2016 calendar year or tax year beginning and ending= B Check it C Name of organization D Employer identification number applicable THE US CHARITABLE GIFT TRUST Ochanges C/O EATON VANCE TRUST COMPANY Naem Ochange Dom business as 31-1663020 Initial return Number and street (or P.O. box if mail is not delivered to street address) Room/suite E Telephone number lFinal return/ TWO INTERNATIONAL PLACE 800-836-2414 aed^n City or town, state or province, country, and ZIP or foreign postal code G Gross receipts $ 285,448,602. = Amended return BOSTON, MA 02110 H(a) Is this a group return Lttionlica- F Name and address of principal officer JEFFREY P. BEALE for subordinates? E]Yes ® No pending SAME AS C ABOVE H(b) Are all subordinates included70 Yes Li No I Tax-exempt status X 501(c)(3) 501(6) ( )A (insert no.) L-J 4947(a)( or 77527 If "No," attach a list (see instructions) HTTP : / /WWW. USCHARITABLEGIFTTRUST. ORG J Website: ► K Form of organization: Corporation X Trust L_J Association L_J Year of State of leaal domicile: DE Part I Summary CD 1 Briefly describe the organization's mission or most significant activities- PROVIDE GIFTS TO VARIOUS PUBLIC a CHARITIES FOR ITS STATED EXEMPT PURPOSE.
    [Show full text]
  • 2020 Annual Report Products
    Products 2020 Annual Report From the CEO Dear Fellow Shareholders, Perrigo’s transformation to a pure-play Consumer Self-Care Company has come a long way LQMXVWWZRVKRUW\HDUV:HKDYHUHVWRUHGVXVWDLQDEOHWRSOLQHJURZWKGHOLYHUHGRQRXU¿QDQFLDO SURPLVHVUHFRQ¿JXUHGRXUSRUWIROLRRIEXVLQHVVHVXSGDWHGWKH,7LQIUDVWUXFWXUHDQGSURFHVVHV of the Company, expanded capacity, upgraded leadership talent, installed business intelligence capabilities, built a new product pipeline of over $500 million and re-instilled a sense of pride and energy among our 11,000 team members. Making this even more remarkable, is that we kept the WUDQVIRUPDWLRQRQWUDFNLQWKHIDFHRIWKHJOREDO&29,'SDQGHPLF,KRSH\RXDUHDVSURXGRI3HUULJR¶VJOREDOWHDP DV,DPIRUKRZWKH\ZRUNHGWRNHHSHDFKRWKHUVDIHNHSWRXUHVVHQWLDOSURGXFWVÀRZLQJDQGNHSWRXUWUDQVIRUPDWLRQ to a consumer self-care company on track through all of the personal and professional uncertainty that came their way LQ7KH\DUHKHURHV As a result of their efforts, Perrigo delivered strong net sales growth for the second year in a row in 2020 and World-wide Consumer sales reached a new record high. Equally important, the team stabilized adjusted operating income after a few years of decline even as we invested over $50 million in our business and overcame $35 million RIXQSODQQHGKHDGZLQGVGXHSULPDULO\WR&29,'UHODWHGVDIHW\FRVWVDQGEXVLQHVVLPSDFWIURPWKHZHDNFROG FRXJKDQGÀXVHDVRQUHODWHGWR&29,'¶VLPSDFWRQSXEOLFOLIH$OOLQDOOZHKDGDYHU\VWURQJ\HDU Our transformation efforts reached an essential milestone after the year closed when we announced the sale of RXU3UHVFULSWLRQ3KDUPDFHXWLFDOVEXVLQHVVWR$OWDULV&DSLWDO3DUWQHUV//&7KHWUDQVDFWLRQUHLQIRUFHVRXUDELOLW\
    [Show full text]
  • Quarterly Federal Court Litigation Status Report
    QUARTERLY FEDERAL COURT LITIGATION STATUS REPORT Office of the General Counsel Bureau of Competition Bureau of Consumer Protection Regional Offices March 31, 2017 No. 131 TABLE OF CONTENTS SUMMARY OF CASES................................................................................................................. ii PETITIONS FOR REVIEW ........................................................................................................... 1 A) Orders to Cease and Desist ............................................................................................ 1 B) Rulemakings ................................................................................................................... 2 INJUNCTION AND CONSUMER REDRESS CASES ................................................................ 3 A) Preliminary Injunctions (Mergers/Acquisitions) ............................................................ 3 B) Preliminary Injunctions (Other) ..................................................................................... 4 C) Permanent Injunctions/Consumer Redress ..................................................................... 4 CIVIL PENALTY AND ENFORCEMENT CASES ................................................................... 82 A) Consumer Protection .................................................................................................... 82 B) Competition .................................................................................................................. 89 SUBPOENA AND CID ENFORCEMENT
    [Show full text]
  • GLAXOSMITHKLINE LLC V. TEVA PHARMACEUTICALS USA, INC
    Case: 18-1976 Document: 111 Page: 1 Filed: 10/02/2020 United States Court of Appeals for the Federal Circuit ______________________ GLAXOSMITHKLINE LLC, SMITHKLINE BEECHAM (CORK) LIMITED, Plaintiffs-Appellants v. TEVA PHARMACEUTICALS USA, INC., Defendant-Cross-Appellant ______________________ 2018-1976, 2018-2023 ______________________ Appeals from the United States District Court for the District of Delaware in No. 1:14-cv-00878-LPS-CJB, Chief Judge Leonard P. Stark. ______________________ Decided: October 2, 2020 ______________________ JUANITA ROSE BROOKS, Fish & Richardson, PC, San Diego, CA, argued for plaintiffs-appellants. Also represented by MICHAEL ARI AMON, CRAIG E. COUNTRYMAN, JONATHAN ELLIOT SINGER; ELIZABETH M. FLANAGAN, MICHAEL J. KANE, WILLIAM WOODFORD, Minneapolis, MN; DOUGLAS E. MCCANN, Wilmington, DE. WILLIAM M. JAY, Goodwin Procter LLP, Washington, DC, argued for defendant-cross-appellant. Also represented by JAIME ANN SANTOS; ELAINE BLAIS, J. Case: 18-1976 Document: 111 Page: 2 Filed: 10/02/2020 2 GLAXOSMITHKLINE LLC v. TEVA PHARMACEUTICALS USA, INC. ANTHONY DOWNS, ROBERT FREDERICKSON, III, CHRISTOPHER T. HOLDING, ALEXANDRA LU, LANA S. SHIFERMAN, DARYL L. WIESEN, Boston, MA; IRA J. LEVY, New York, NY. HANSJORG SAUER, Biotechnology Innovation Organization, Washington, DC, for amicus curiae Biotechnology Innovation Organization. Also represented by MELISSA A. BRAND; BRIAN PAUL BARRETT, Eli Lilly and Company, Indianapolis, IN. MICHAEL N. KENNEDY, Covington & Burling LLP, Washington, DC, for amicus curiae Pharmaceutical Research and Manufacturers of America. Also represented by STEVEN JOHN WINKELMAN; DAVID EVAN KORN, Pharmaceutical Research and Manufacturers Association of America, Washington, DC. ANDREW CURTIS NICHOLS, Winston & Strawn LLP, Washington, DC, for amicus curiae Association for Accessible Medicines. Also represented by GEORGE C.
    [Show full text]
  • 20200313170134437 to FILE --Actavis Contrave Cert Petition.Pdf
    No. IN THE Supreme Court of the United States ACTAVIS LABORATORIES FL, INC., Petitioner, v. NALPROPION PHARMACEUTICALS LLC Respondent. On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit PETITION FOR A WRIT OF CERTIORARI GERARD J. CEDRONE WILLIAM M. JAY THOMAS MCTIGUE IV Counsel of Record GOODWIN PROCTER LLP JAIME A. SANTOS 100 Northern Avenue GOODWIN PROCTER LLP Boston, MA 02210 1900 N Street, N.W. Washington, DC 20036 SCOTT J. BORNSTEIN [email protected] JONATHAN D. BALL (202) 346-4000 RICHARD C. PETTUS JUSTIN A. MACLEAN ALEXANDRA D. VALENTI GREENBERG TRAURIG LLP GOODWIN PROCTER LLP 200 Park Avenue 620 Eighth Avenue New York, NY 10166 New York, NY 10018 March 13, 2020 Counsel for Petitioner QUESTION PRESENTED Under 35 U.S.C. § 112, a patent’s specification must “contain a written description of the invention.” That requirement, a cornerstone of federal patent law, ensures that an inventor can claim patent pro- tection only for what she actually invented. Consistent with this Court’s longstanding di- rective that every element of a patent claim must be treated as material, the Federal Circuit has long held that all elements of a patent’s claims must ac- tually be disclosed in the patent’s specification. But the Federal Circuit has now broken from that estab- lished rule. In the 2-1 decision below, the Federal Circuit announced for the first time that for some claim limitations, a “substantially equivalent” disclo- sure will do. Here, although the claims expressly re- quire testing using one specific method identified by name, the court held that the written description’s disclosure of a different testing method was good enough.
    [Show full text]
  • Trazodone Hydrochloride Tablets, Usp
    TRAZODONE HYDROCHLORIDE- trazodone hydrochloride tablet Lake Erie Medical DBA Quality Care Products LLC ---------- TRAZODONE HYDROCHLORIDE TABLETS, USP Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of trazodone HCl or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Trazodone HCl is not approved for use in pediatric patients. (See WARNINGS, Clinical Worsening and Suicide Risk, PRECAUTIONS, Information for Patients, and PRECAUTIONS, Pediatric Use DESCRIPTION Trazodone Hydrochloride Tablets USP is an antidepressant chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. Trazodone hydrochloride is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-1, 2, 4-triazolo[4, 3-a]-pyridin- 3(2H)-one hydrochloride. It is a white odorless crystalline powder which is freely soluble in water.
    [Show full text]
  • Printmgr File
    SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2011 Commission File Number 0-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Translation of registrant’s name into English) 5 Basel Street, P.O. Box 3190 Petach Tikva 49131 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ⌧ Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): TEVA PHARMACEUTICAL INDUSTRIES LIMITED INDEX Page Consolidated Statements of Income 2 Consolidated Balance Sheets 3 Consolidated Statements of Cash Flow 4 Notes to Condensed Consolidated Financial Statements 5 Operating and Financial Review and Prospects 23 Risk Factors 43 Quantitative and Qualitative Disclosures About Market Risk 44 Legal Proceedings 44 Exhibits As listed below, attached as Exhibit 101 to this Report on Form 6-K is certain information contained in this Report on Form 6-K of Teva Pharmaceutical Industries Limited relating to the three and nine months ended September 30, 2011, formatted in XBRL (Extensible Business Reporting Language). Users of this data are advised, in accordance with Rule 406T of Regulation S-T promulgated by the Securities and Exchange Commission, that this Interactive Data File is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.
    [Show full text]
  • 2020 Or Tax Year Beginning , 2020, and Ending , 20 Name of Foundation a Employer Identification Number MCLEAN CONTRIBUTIONSHIP 23-6396940 Number and Street (Or P.O
    OMB No. 1545-0047 Form 990-PF Return of Private Foundation or Section 4947(a)(1) Trust Treated as Private Foundation Do not enter social security numbers on this form as it may be made public. Department of the Treasury Internal Revenue Service Go to www.irs.gov/Form990PF for instructions and the latest information. Open to Public Inspection For calendar year 2020 or tax year beginning , 2020, and ending , 20 Name of foundation A Employer identification number MCLEAN CONTRIBUTIONSHIP 23-6396940 Number and street (or P.O. box number if mail is not delivered to street address) Room/suite B Telephone number (see instructions) 230 SUGARTOWN ROAD (610) 989-8090 City or town, state or province, country, and ZIP or foreign postal code C If exemption application is pending, check here WAYNE, PA 19087 G Check all that apply: Initial return Initial return of a former public charity D 1. Foreign organizations, check here Final return Amended return 2. Foreign organizations meeting the Address change Name change 85% test, check here and attach computation H Check type of organization:X Section 501(c)(3) exempt private foundation E If private foundation status was terminated Section 4947(a)(1) nonexempt charitable trust Other taxable private foundation under section 507(b)(1)(A), check here X I Fair market value of all assets at J Accounting method: Cash Accrual F If the foundation is in a 60-month termination end of year (from Part II, col. (c), line Other (specify) under section 507(b)(1)(B), check here 16) $ 68,764,997.
    [Show full text]